Profound Medical

PROF · TORONTO

$5.56−$0.20 (−3.47%)TodayMarket closed · Oct 23, 7:52 PM ET

Prev close $5.76

PROF analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $8.31 (+49.5% upside)

Low: $8.23
Now: $5.56
High: $8.56

Upgrades and downgrades

The latest rating actions, newest first

PROF analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Lake Street	Jan 7, 2026	Maintains	Buy	$11.00 → $12.00	33%

The case for and against

Updated Nov 27, 2024

Bull case

Profound Medical Corp is strategically positioning itself for growth, anticipating an increase in its US installed base of TULSA-PRO systems from approximately 53 to 75 by the end of 2024, bolstered by a mixed revenue model comprising capital placements and recurring revenue. The upcoming changes to TULSA reimbursement, including the introduction of an ASC code in early 2024 and CPT codes in early 2025, are expected to significantly enhance access to prostate cancer treatments, potentially increasing the installed base substantially. Additionally, advancements in the TULSA-PRO system, notably through recent software enhancements like the “Thermal Boost Pro,” underscore the growing physician comfort with the technology, which reflects positively on the company's long-term utilization growth potential.

Bear case

Profound Medical Corp's reliance on the success of its TULSA-PRO system and associated CAPTAIN study significantly heightens the company's risk profile, as failure in these areas could lead to diminished adoption rates and worsening reimbursement prospects. The company's single-technology focus further exacerbates this risk, as an ineffective sales strategy could result in stalled or declining revenue growth. Additionally, adverse clinical data or negative recommendations from medical societies could severely impact the product's market acceptance and overall commercial potential amidst a challenging funding and valuation environment in the MedTech sector.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.